TY - JOUR
T1 - Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
AU - Rossi, Davide
AU - Rasi, Silvia
AU - Fabbri, Giulia
AU - Spina, Valeria
AU - Fangazio, Marco
AU - Forconi, Francesco
AU - Marasca, Roberto
AU - Laurenti, Luca
AU - Bruscaggin, Alessio
AU - Cerri, Michaela
AU - Monti, Sara
AU - Cresta, Stefania
AU - Famà, Rosella
AU - De Paoli, Lorenzo
AU - Bulian, Pietro
AU - Gattei, Valter
AU - Guarini, Anna
AU - Deaglio, Silvia
AU - Capello, Daniela
AU - Rabadan, Raul
AU - Pasqualucci, Laura
AU - Dalla-Favera, Riccardo
AU - Foà, Robin
AU - Gaidano, Gianluca
PY - 2012/1/12
Y1 - 2012/1/12
N2 - Analysis of the chronic lymphocytic leukemia (CLL) coding genome has recently disclosed that the NOTCH1 proto-oncogene is recurrently mutated at CLL presentation. Here, we assessed the prognostic role of NOTCH1 mutations in CLL. Two series of newly diagnosed CLL were used as training (n = 309) and validation (n = 230) cohorts. NOTCH1 mutations occurred in 11.0% and 11.3% CLL of the training and validation series, respectively. In the training series, NOTCH1 mutations led to a 3.77-fold increase in the hazard of death and to shorter overall survival (OS; P < .001). Multivariate analysis selected NOTCH1 mutations as an independent predictor of OS after controlling for confounding clinical and biologic variables. The independent prognostic value of NOTCH1 mutations was externally confirmed in the validation series. The poor prognosis conferred by NOTCH1 mutations was attributable, at least in part, to shorter treatment-free survival and higher risk of Richter transformation. Although NOTCH1 mutated patients were devoid of TP53 disruption in more than 90% cases in both training and validation series, the OS predicted by NOTCH1 mutations was similar to that of TP53 mutated/deleted CLL. NOTCH1 mutations are an independent predictor of CLL OS, tend to be mutually exclusive with TP53 abnormalities, and identify cases with a dismal prognosis.
AB - Analysis of the chronic lymphocytic leukemia (CLL) coding genome has recently disclosed that the NOTCH1 proto-oncogene is recurrently mutated at CLL presentation. Here, we assessed the prognostic role of NOTCH1 mutations in CLL. Two series of newly diagnosed CLL were used as training (n = 309) and validation (n = 230) cohorts. NOTCH1 mutations occurred in 11.0% and 11.3% CLL of the training and validation series, respectively. In the training series, NOTCH1 mutations led to a 3.77-fold increase in the hazard of death and to shorter overall survival (OS; P < .001). Multivariate analysis selected NOTCH1 mutations as an independent predictor of OS after controlling for confounding clinical and biologic variables. The independent prognostic value of NOTCH1 mutations was externally confirmed in the validation series. The poor prognosis conferred by NOTCH1 mutations was attributable, at least in part, to shorter treatment-free survival and higher risk of Richter transformation. Although NOTCH1 mutated patients were devoid of TP53 disruption in more than 90% cases in both training and validation series, the OS predicted by NOTCH1 mutations was similar to that of TP53 mutated/deleted CLL. NOTCH1 mutations are an independent predictor of CLL OS, tend to be mutually exclusive with TP53 abnormalities, and identify cases with a dismal prognosis.
UR - http://www.scopus.com/inward/record.url?scp=84855854025&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-09-379966
DO - 10.1182/blood-2011-09-379966
M3 - Article
SN - 0006-4971
VL - 119
SP - 521
EP - 529
JO - Blood
JF - Blood
IS - 2
ER -